Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To determine the extent of and reasons for hesitancy toward vaccination among adults at high-risk for pneumococcal disease.
Design: Cross-sectional.
Setting: Online survey in March-April 2019 via QuestionPro.
Subjects: Tennessee adults (18-64 years) at high-risk of pneumococcal disease (n = 1,002).
Measures: Modified version of the validated Vaccine Hesitancy Scale assessed vaccine-related beliefs, reasons for hesitancy, external influences on vaccination, and prior vaccination.
Analysis: Descriptive and inferential statistics provided an overview of the responses and comparisons among subgroups. Logistic regression determined the odds of being hesitant using the listed beliefs and influencers as predictors. Thematic analysis was performed on the qualitative data gathered from free response questions throughout the survey.
Results: Analysis included 1,002 complete responses (12% response rate [total viewed = 8,331]) with 34.3% indicating hesitancy toward one or more recommended vaccinations, with 53% of which indicating hesitancy to the pneumococcal vaccine despite it being recommended by the Advisory Committee on Immunization Practices (ACIP) for all respondents. The odds of vaccine hesitancy or resistance were higher in minorities (OR: 1.6; 95% CI: 1.19-2.11), those not believing others like them get vaccinated (OR: 1.82; 95% CI: 1.262-2.613), and respondents recalling negative media about vaccines (OR: 2.56; 95% CI: 1.797-3.643).
Conclusions: Patients at high-risk of pneumococcal disease lack awareness of the need for the recommended vaccine, and provider education may need improving to increase vaccination in this population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0890117121998141 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pneumococcal vaccination incentive campaign in chronic heart failure patients in France: a cluster-randomized trial.
Eur J Prev Cardiol
August 2025
University Hospital of Montpellier, Montpellier, France.
Background: Pneumococcal vaccination rates are critically low among high-risk patients, particularly those with heart failure (HF), who face increased risk of severe infections and complications. There is limited evidence on the effectiveness of simple interventions to improve vaccination uptake in this population.
Objectives: A prospective interventional trial was designed to evaluate the impact of an incentive campaign carried out by the French health insurance.
Dose-sparing effects of novel adjuvants and aluminum hydroxide on two different vaccines in a neonatal mouse model.
Front Immunol
August 2025
Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavík, Iceland.
Childhood vaccination provides protection against infectious diseases, but multiple vaccinations are required to achieve this. In situations like influenza epidemics or COVID-19 pandemic, vaccine demands may exceed production capacity, highlighting the need for dose-sparing strategies. Adjuvants can boost and modulate immune responses to vaccines and could reduce the antigen doses needed to confer protection.
View Article and Find Full Text PDFHigh Propensity for Multidrug-Resistant Pneumococcal Shedding Among Adults Living With HIV on Stable Antiretroviral Therapy in Malawi.
Open Forum Infect Dis
August 2025
Infection and Immunity Research Group, Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
Background: People living with human immunodeficiency virus (HIV; PLHIV) on antiretroviral therapy (ART) are still at risk of pneumococcal disease and have over 2-fold higher pneumococcal carriage prevalence than HIV-uninfected (HIV-) adults). Carriage is a risk factor for pneumococcal disease, antimicrobial resistance (AMR) emergence, and transmission. Therefore, we tested whether the high prevalence of pneumococcal carriage in PLHIV on ART is associated with increased bacterial density, shedding, and AMR.
View Article and Find Full Text PDFUptake of Pneumococcal Vaccines Among U.S. Adults After 2022 Update to Recommendations.
AJPM Focus
October 2025
Avalere Health, Washington, District of Columbia.
Introduction: Updated recommendations for adult pneumococcal vaccination in the U.S. (publication date: January 27, 2022) incorporated 2 new vaccines (15- and 20-valent pneumococcal conjugate vaccines), removed 13-valent pneumococcal conjugate vaccine, and called for pneumococcal conjugate vaccine use among immunocompetent adults aged 19-64 years with certain medical conditions.
View Article and Find Full Text PDFFactors associated with willingness among adults to receive pneumococcal vaccine in Hong Kong: a cross-sectional study using HBM constructs.
Vaccine
July 2025
The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; Centre for Health Education and Health Promotion, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. Electronic address: wong_martin@
Objectives: Pneumococcal infections pose a significant global health risk, especially for elderly and immunocompromised populations. This study explores the willingness of Hong Kong adults aged 18-64 years with risk conditions of pneumococcal and aged 65 years or above to receive the pneumococcal vaccine and identifies the factors influencing this willingness.
Methods: A territory-wide cross-sectional survey was conducted between December 2024 and February 2025 among the Hong Kong adults aged 18-64 years with risk conditions of pneumococcal and aged 65 years or above.